The study was conducted at the Regina Elena Cancer Institute, Rome, Italy. This work was presented at the ACVIM Forum 2009, Montreal, Quebec, Canada.
Evaluation of Cisplatin as an Electrochemotherapy Agent for the Treatment of Incompletely Excised Mast Cell Tumors in Dogs
Version of Record online: 11 FEB 2011
Copyright © 2011 by the American College of Veterinary Internal Medicine
Journal of Veterinary Internal Medicine
Volume 25, Issue 2, pages 407–411, March/April 2011
How to Cite
Spugnini, E.P., Vincenzi, B., Citro, G., Dotsinsky, I., Mudrov, T. and Baldi, A. (2011), Evaluation of Cisplatin as an Electrochemotherapy Agent for the Treatment of Incompletely Excised Mast Cell Tumors in Dogs. Journal of Veterinary Internal Medicine, 25: 407–411. doi: 10.1111/j.1939-1676.2011.0678.x
- Issue online: 7 MAR 2011
- Version of Record online: 11 FEB 2011
- Submitted December 16, 2009; Revised September 29, 2010; Accepted December 14, 2010.
- 1Mast cell tumors. In: WithrowSJ, MacEwenEG, eds. Small Animal Clinical Oncology, 4rd ed. Philadelphia, PA: WB Saunders Co; 2007:402–424.,
- 2Recurrence rate, clinical outcome, and cellular proliferation indices as prognostic indicators after incomplete surgical excision of cutaneous grade II mast cell tumors: 28 dogs (1994–2002). J Vet Intern Med 2006;20:933–940., , , et al.
- 3Prognosis following surgical excision of canine cutanous mast cell tumors with histopathologically tumor-free versus nontumor-free margins: A retrospective study of 31 cases. J Am Anim Hosp Assoc 2002;38:458–466., , , et al.